SCHEMBL19784441

SCHEMBL19784441

CCOC(=O)CCCCCN(O)C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
ALOX5 P09917 1/20 0.43
CYP1A2 P05177 1/20 0.42
GAA P10253 1/20 0.41
ALDH1A1 P00352 3/20 0.40
TDP1 Q9NUW8 3/20 0.40
ALOX15 P16050 2/20 0.40
CYP3A4 P08684 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KDM5A P29375 4/20 0.40
DNM1 Q05193 1/20 0.40
DGKA P23743 1/20 0.39
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
KMT2A Q03164 2/20 0.37
USP2 O75604 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5655019 0.85 HDAC1 (0.44) HDAC1HDAC2HDAC6CYP1A2GAA
SCHEMBL8887438 0.80 HDAC1 (0.40) HDAC1HDAC2HDAC6KDM5ADNM1
SCHEMBL15055158 0.80 CYP1A2 (0.53) HDAC1HDAC2HDAC6CYP1A2GAA
SCHEMBL27643241 0.80 CYP1A2 (0.53) HDAC1HDAC2HDAC6CYP1A2GAA
SCHEMBL26648449 0.80 CYP1A2 (0.53) HDAC1HDAC2HDAC6CYP1A2GAA
SCHEMBL29285429 0.80 CA14 (0.47) HDAC1HDAC2HDAC6ALOX5CYP1A2
SCHEMBL7344626 0.79 CYP1A2 (0.40) HDAC1HDAC2HDAC6CYP1A2GAA
SCHEMBL21937996 0.79 CA14 (0.41) HDAC1HDAC2HDAC6KDM5AKDM4C
SCHEMBL27643221 0.78 CYP1A2 (0.55) CYP1A2GAAALDH1A1TDP1ALOX15
SCHEMBL1272960 0.78 CA14 (0.49) HDAC1HDAC2HDAC6ALOX5CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210369848-A1 Conjugation Method for Carrier-Linked Prodrugs Ascendls Pharma A/S (DK) 2021-12-02 US disclosed
WO-2018011266-A1 CONJUGATION METHOD FOR CARRIER-LINKED PRODRUGS ASCENDIS PHARMA A/S (DK) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210369848-A1 Conjugation Method for Carrier-Linked Prodrugs UGT2B7, SLC10A1, UGT1A6 HDAC1 716/4885HDAC2 753/4885HDAC6 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.